PL430029A1 - Kompozycja doustna zawierająca beta-escynę do obniżania toksyczności acetaldehydu - Google Patents

Kompozycja doustna zawierająca beta-escynę do obniżania toksyczności acetaldehydu

Info

Publication number
PL430029A1
PL430029A1 PL430029A PL43002917A PL430029A1 PL 430029 A1 PL430029 A1 PL 430029A1 PL 430029 A PL430029 A PL 430029A PL 43002917 A PL43002917 A PL 43002917A PL 430029 A1 PL430029 A1 PL 430029A1
Authority
PL
Poland
Prior art keywords
escin
subject
present
acetaldehyde toxicity
extract
Prior art date
Application number
PL430029A
Other languages
English (en)
Polish (pl)
Inventor
Katarzyna KOZIAK
Original Assignee
Escilab Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Escilab Spółka Z Ograniczoną Odpowiedzialnością filed Critical Escilab Spółka Z Ograniczoną Odpowiedzialnością
Publication of PL430029A1 publication Critical patent/PL430029A1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/73Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
PL430029A 2016-11-24 2017-11-24 Kompozycja doustna zawierająca beta-escynę do obniżania toksyczności acetaldehydu PL430029A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1619846.7A GB201619846D0 (en) 2016-11-24 2016-11-24 Saponin composition
PCT/IB2017/057395 WO2018096502A1 (en) 2016-11-24 2017-11-24 Oral compositions comprising beta-escin for reducing acetaldehyde toxicity

Publications (1)

Publication Number Publication Date
PL430029A1 true PL430029A1 (pl) 2021-03-08

Family

ID=58073282

Family Applications (2)

Application Number Title Priority Date Filing Date
PL430029A PL430029A1 (pl) 2016-11-24 2017-11-24 Kompozycja doustna zawierająca beta-escynę do obniżania toksyczności acetaldehydu
PL17812273.5T PL3544615T3 (pl) 2016-11-24 2017-11-24 Kompozycja doustna zawierająca beta-escynę i sok z aronii do obniżania toksyczności aldehydu octowego

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17812273.5T PL3544615T3 (pl) 2016-11-24 2017-11-24 Kompozycja doustna zawierająca beta-escynę i sok z aronii do obniżania toksyczności aldehydu octowego

Country Status (9)

Country Link
US (1) US10799550B2 (cg-RX-API-DMAC7.html)
EP (1) EP3544615B1 (cg-RX-API-DMAC7.html)
JP (1) JP7070933B2 (cg-RX-API-DMAC7.html)
KR (1) KR102569055B1 (cg-RX-API-DMAC7.html)
AU (1) AU2017365116B2 (cg-RX-API-DMAC7.html)
CA (1) CA3044504A1 (cg-RX-API-DMAC7.html)
GB (1) GB201619846D0 (cg-RX-API-DMAC7.html)
PL (2) PL430029A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018096502A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2992157T3 (es) * 2018-10-05 2024-12-09 Escilab Sp Z O O Composición oral que comprende b-escina y el uso de la misma
CN116159145B (zh) * 2023-01-31 2025-04-22 四川大学 含七叶皂苷和/或其盐化合物的转染复合物在促转染的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3533231B2 (ja) * 1993-08-20 2004-05-31 森下仁丹株式会社 アルコール吸収抑制剤
JP4777495B2 (ja) * 1999-04-01 2011-09-21 森下仁丹株式会社 アルコール障害予防剤およびそれを含有する食品
DK1976391T3 (da) * 2005-12-30 2011-01-10 Cadbury Holdings Ltd Tyggegummipræparat indeholdende aroniabær
KR101383276B1 (ko) * 2012-03-05 2014-04-08 염장열 아로니아 음료 농축액 및 그 제조방법
KR20140090453A (ko) * 2013-01-09 2014-07-17 (주) 제이비케이자연의학연구소 아로니아 추출물을 함유하는 숙취예방, 숙취해소 또는 간 보호용 조성물
PL405318A1 (pl) * 2013-09-11 2015-03-16 Cezary Bilski Preparat złożony wspomagający odchudzanie na bazie wyciągów roślinnych
KR20160100572A (ko) * 2015-02-16 2016-08-24 학교법인연세대학교 고미가 제거된 남가새 음료 및 이의 제조방법
EP3078381A1 (en) * 2015-04-10 2016-10-12 Warszawski Uniwersytet Medyczny Horse chestnut extract or escins for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
US10799550B2 (en) 2020-10-13
JP7070933B2 (ja) 2022-05-18
AU2017365116B2 (en) 2023-06-22
JP2019535779A (ja) 2019-12-12
KR20190087437A (ko) 2019-07-24
US20190321432A1 (en) 2019-10-24
KR102569055B1 (ko) 2023-08-21
EP3544615B1 (en) 2022-05-18
PL3544615T3 (pl) 2022-09-19
EP3544615A1 (en) 2019-10-02
CA3044504A1 (en) 2018-05-31
WO2018096502A1 (en) 2018-05-31
AU2017365116A1 (en) 2019-05-23
GB201619846D0 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
WO2007081773A3 (en) Treatment of fatty liver
PH12017502092A1 (en) Topical pharmaceutical compositions
MX344787B (es) Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.
MY209059A (en) Aqueous ophthalmic composition comprising diquafosol or salt thereof and polyvinylpyrrolidone
TN2015000555A1 (en) Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase
HRP20160406T1 (hr) Postupci i pripravci za liječenje sa štitnjačom povezanih medicinskih stanja sa sniženiim folatima
UA90668C2 (ru) Состав для лечения хронической венозной недостаточности, который содержит водный экстракт листьев красного винограда и противовоспалительное средство
PL430029A1 (pl) Kompozycja doustna zawierająca beta-escynę do obniżania toksyczności acetaldehydu
MX2022015799A (es) Composicion y metodo para el tratamiento del dolor cronico.
AR110800A1 (es) MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2’-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA
BR112014000182A2 (pt) mascaramento do amargor
RU2019105734A (ru) Фармацевтическая композиция для применения при лечении патологий простаты
NO20075945L (no) Behandling, prevensjon og ameliorasjon av lungelidelser assosiert med kjemoterapi eller radioterapi med aktive vitamin D sammensetninger eller imitatorer derav
EA201992826A1 (ru) 15бета-[3-пропанамидо]-замещенные эстра-1,3,5(10)-триен-17-оны и их 17-оксимы для применения в ингибировании 17бета-гидроксистероиддегидрогеназ
HRP20211488T1 (hr) Sastav i metoda za liječenje metaboličkih poremećaja
HRP20250972T1 (hr) Farmaceutski pripravak za prevenciju i/ili liječenje atopijskog dermatitisa koji sadrži il-31 antagonist kao djelatni sastojak
MX2023000899A (es) Administracion de beta-hidroxibutirato y compuestos relacionados en humanos para el tratamiento y/o prevencion de enfermedades respiratorias.
MX2016008546A (es) Reduccion de queloides utilizando alantoina topica.
TW201511766A (zh) 用於增進男性性健康之方法及組合物
DK1827136T3 (da) Sammensætning til oral indgivelse med sundhedsfremmende virkning på hjerte-kredslöbs-systemet
NZ733658A (en) Compositions and methods for chronic use of a weight-gaining compound
PL423673A1 (pl) Kompozycja do podawania doustnego, zastosowanie kompozycji w zapobieganiu i leczeniu mucositis oraz sposób leczenia mucositis
PH12022553179A1 (en) A pharmarceutical composition capable of inhibiting replication of coronavirus
FI20135503A7 (fi) Kysteiini tai sen johdannainen atrofisen gastriitin hoitamiseen
DE60035771D1 (de) Verwendung eines den plasma homocysteingehalt reduzierenden wirkstoffs zur verminderung des risikos der durch gestagen hormone verursachten thromboembolischen nebenwirkungen